Ardea Biosciences to Present at the UBS Global Life Sciences Conference and the Third Annual JMP Securities Healthcare Focus Con
September 17 2008 - 8:00AM
PR Newswire (US)
SAN DIEGO, Sept. 17 /PRNewswire-FirstCall/ -- Ardea Biosciences,
Inc. (NASDAQ:RDEA) announced today that Barry D. Quart, PharmD,
President and CEO of Ardea Biosciences, will present at two
upcoming investor conferences. UBS Global Life Sciences Conference
Date: Wednesday, September 24, 2008 Time: 1:00 p.m. Eastern Time
Location: Grand Hyatt, New York Webcast: http://www.ibb.ubs.com/
Third Annual JMP Securities Healthcare Focus Conference Date:
Tuesday, October 7, 2008 Time: 2:00 p.m. Eastern Time Location: Le
Parker Meridian, New York Webcast:
http://www.ljfevents.com/jmp/CompanyReg.htm About Ardea
Biosciences, Inc. Ardea Biosciences, Inc., of San Diego,
California, is a biotechnology company focused on the discovery and
development of small-molecule therapeutics for the treatment of
HIV, gout, cancer and inflammatory diseases. We have five product
candidates in clinical trials and others in preclinical development
and discovery. Our most advanced product candidate is RDEA806, a
non-nucleoside reverse transcriptase inhibitor (NNRTI), which has
successfully completed a Phase 2a study for the treatment of
patients with HIV. We have evaluated our second-generation NNRTI
for the treatment of HIV, RDEA427, in a human micro-dose
pharmacokinetic study and have selected it for clinical
development. RDEA594, our lead product candidate for the treatment
of gout, is being evaluated in a Phase 1 clinical trial and is
believed to be an inhibitor of the URAT1 transporter in the kidney,
which is responsible for regulation of uric acid levels. We are
evaluating our lead MEK inhibitor, RDEA119, in a Phase 1 study in
advanced cancer patients, and have completed a Phase 1 study in
normal healthy volunteers as a precursor to trials in patients with
inflammatory diseases. Lastly, we have evaluated our
second-generation MEK inhibitor for the treatment of cancer and
inflammatory diseases, RDEA436, in a human micro-dose
pharmacokinetic study and have selected it for clinical
development. Statements contained in this press release regarding
matters that are not historical facts are "forward-looking
statements" within the meaning of the Private Securities Litigation
Reform Act of 1995. Because such statements are subject to risks
and uncertainties, actual results may differ materially from those
expressed or implied by such forward-looking statements. Such
statements include, but are not limited to, statements regarding
our goals, including the expected properties and benefits of
RDEA806, RDEA427, RDEA594, RDEA119, RDEA436 and our other compounds
and the results of preclinical, clinical and other studies. Risks
that contribute to the uncertain nature of the forward- looking
statements include: risks related to the outcome of preclinical and
clinical studies, risks related to regulatory approvals, delays in
commencement of preclinical and clinical studies, and costs
associated with our drug discovery and development programs and
business development activities. These and other risks and
uncertainties are described more fully in our most recently filed
SEC documents, including our Annual Report on Form 10-K and our
Quarterly Reports on Form 10-Q, under the headings "Risk Factors."
All forward-looking statements contained in this press release
speak only as of the date on which they were made. We undertake no
obligation to update such statements to reflect events that occur
or circumstances that exist after the date on which they were made.
DATASOURCE: Ardea Biosciences, Inc. CONTACT: Investors, John Beck
of Ardea Biosciences, +1-858-652-6523, ; or Media, Edie DeVine of
WeissComm Partners, +1-415-946-1081, , for Ardea Biosciences, Inc.
Copyright
Ardea Biosciences, Inc. (MM) (NASDAQ:RDEA)
Historical Stock Chart
From Jun 2024 to Jul 2024
Ardea Biosciences, Inc. (MM) (NASDAQ:RDEA)
Historical Stock Chart
From Jul 2023 to Jul 2024